StockpollyBeta
Get App
Popularity #759
ARWR · NASDAQ · Biotechnology

Arrowhead Pharmaceuticals (ARWR)

Develops targeted RNAi medicines and markets REDEMPLO for familial chylomicronemia syndrome.

$71.96
vs last close+3.17 (+4.61%)

In millions of USD, except per-share figures

In millionsQ4 FY23Sep 2023Q1 FY24Dec 2023Q2 FY24Mar 2024Q3 FY24Jun 2024Q4 FY24Sep 2024Q1 FY25Dec 2024Q2 FY25Mar 2025Q3 FY25Jun 2025Q4 FY25Sep 2025Q1 FY26Dec 2025Q2 FY26Mar 2026Q3 FY26Jun 2026
Revenue1640003543282562647475
Cost of revenue445550000000
Gross profit12−1−5−5−53543282562647475
121136122171157164162193212223215245
Research & development9611397148131137133162175177173198
242325232626283037464147
General & administrative24232523262628303746410
Other expenses000001111110
Operating income−108−137−126−176−162−161381−1664441−141−170
−1−2−12−11−14−12−14−8−134−9
Interest income43667810119101717
Interest expense55751522222422232425
Other non-operating income−5−3−6−7−4−8−10−11−14−10−28−16
Income before tax−109−139−127−174−173−175370−1793628−138−179
Income tax expense2−300102020000
Net income from continuing operations−111−135−127−174−173−175368−1791628−138−179
Net income−110−133−125−171−171−173370−175−2431−133−194
EPS, basic−$1.02−$1.24−$1.02−$1.38−$1.40−$1.39$2.78−$1.26−$0.17$0.22−$0.93−$1.36
EPS, diluted−$1.02−$1.24−$1.02−$1.38−$1.40−$1.39$2.75−$1.26−$0.17$0.22−$0.93−$1.36
Weighted average shares, basic107107123124122125133139136140142143
Weighted average shares, diluted107107123124122125134139136141142143
EBITDA−100−129−115−164−153−148397−1486457−107−154
Depreciation & amortization445555666660
EBIT−104−133−120−169−158−153391−1555851−114−154